Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KIARA: T-DM1 in HER2-positive Breast Cancer with Brain Metastasis
NCT03203616Phase 2Withdrawn
- Sponsor
- Institut Jules Bordet
- Start
- Feb 2018
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab emtansine in HER2-positive breast cancer and brain metastasis (BM), sponsored by Institut Jules Bordet. Primary endpoint: Clinical Benefit at 9 weeks. Planned start Feb 2018; status: withdrawn.
02
Drugs
trastuzumab emtansine
03
Conditions
HER2-positive breast cancerbrain metastasis (BM)
Beyond the preview
Go deeper on NCT03203616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03203616.